Roivan­t's rare dis­ease shop cap­tures FDA des­ig­na­tions; Chi­na biotech lands $18M launch round

→ Weeks af­ter Alex­ion’s $ALXN Rachelle Jacques jumped ship to as­sume the role of CEO of En­zy­vant Sci­ences — forged out of Vivek Ra­maswamy’s pro­lif­ic shop at Roivant — the rare dis­ease drug­mak­er’s pre­clin­i­cal en­zyme re­place­ment ther­a­py for Far­ber dis­ease, dubbed RVT-801, has won rare pe­di­atric dis­ease and fast track des­ig­na­tions from the FDA.

→ The flow of cash in­to Chi­na’s biotech scene con­tin­ues, with an $18 mil­lion launch round for neoanti­gen up­start GenoIm­mune. GF Xinde In­vest­ment Man­age­ment led the round.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.